David Malcom Rodman - Feb 12, 2024 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Medical Officer
Signature
/s/ Adam Levy, Attorney-in-fact
Stock symbol
MLYS
Transactions as of
Feb 12, 2024
Transactions value $
$9,566
Form type
4
Date filed
2/13/2024, 04:08 PM
Previous filing
Jan 12, 2024
Next filing
Feb 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Options Exercise $2.71K +5.02K +15.25% $0.54* 37.9K Feb 12, 2024 Direct
transaction MLYS Common Stock Options Exercise $6.86K +6.35K +16.74% $1.08* 44.3K Feb 12, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Options Exercise $0 -5.02K -8.33% $0.00 55.2K Feb 12, 2024 Common Stock 5.02K $0.54 Direct F1, F2
transaction MLYS Stock Option Options Exercise $0 -6.35K -2.86% $0.00 216K Feb 12, 2024 Common Stock 6.35K $1.08 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F2 The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
F3 Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F4 The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.